论文部分内容阅读
目的对比不同剂量阿托伐他汀对高脂血症合并2型糖尿病患者的调脂效果。方法选择2014年1月—2016年12月在青海省心脑血管病专科医院诊治的高脂血症合并2型糖尿病患者140例作为研究对象,根据随机原则分为观察组与对照组各70例,对照组给予小剂量阿托伐他汀治疗,观察组给予大剂量阿托伐他汀治疗,都治疗观察4周。比较两组糖脂代谢指标,血脂指标及并发症情况。结果观察组与对照组治疗后的血糖与糖化血红蛋白明显低于治疗前,差异有统计学意义(P<0.05);两组治疗后的血糖与糖化血红蛋白值对比无明显差异。观察组与对照组治疗后的三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)低于治疗前,高密度脂蛋白(HDL-C)高于治疗前,对比差异明显(P<0.05);同时治疗后观察组的TG、TC、LDL-C明显低于对照组,HDL-C明显高于对照组,差异有统计学意义(P<0.05)。治疗后观察组与对照组的总有效率分别为95.7%和97.1%,两组对比差异无统计学意义;治疗后随访调查6个月,观察组的心律失常、心衰、心源性休克等并发症发生率为8.6%,对照组为27.1%,观察组明显少于对照组,差异有统计学意义(P<0.05)。结论阿托伐他汀治疗高脂血症合并2型糖尿病患者具有很好的效果,特别是大剂量阿托伐他汀的应用具有更好的调脂效果,从而减少随访心血管并发症的发生,有很好的应用价值。
Objective To compare the lipid-lowering effects of different doses of atorvastatin on patients with type 2 diabetes and hyperlipidemia. Methods From January 2014 to December 2016, 140 patients with type 2 diabetes and hyperlipidemia diagnosed and treated in Qinghai Cardiovascular and Cardiovascular Hospital were divided into observation group and control group , The control group was treated with low-dose atorvastatin, and the observation group was given high-dose atorvastatin, all of which were treated for 4 weeks. The two groups of glucose and lipid metabolism index, blood lipid indicators and complications were compared. Results The blood glucose and HbA1c after treatment in the observation and control groups were significantly lower than those before treatment (P <0.05). There was no significant difference between the two groups in blood glucose and HbA1c after treatment. The triglyceride (TG), total cholesterol (TC) and low density lipoprotein (LDL-C) in the observation group and the control group after treatment were lower than those before treatment and high density lipoprotein (HDL-C) (P <0.05). The TG, TC and LDL-C in the observation group were significantly lower than those in the control group at the same time, the HDL-C was significantly higher than that of the control group (P <0.05). After treatment, the total effective rates of the observation group and the control group were 95.7% and 97.1%, respectively, with no significant difference between the two groups. After the treatment, the follow-up investigation was 6 months. The arrhythmia, heart failure and cardiogenic shock The complication rate was 8.6% in the control group and 27.1% in the control group, which was significantly lower in the observation group than in the control group (P <0.05). Conclusions Atorvastatin has a good effect in treating patients with type 2 diabetes mellitus with hyperlipidemia. In particular, the application of high-dose atorvastatin has better lipid-lowering effect, thus reducing the incidence of follow-up cardiovascular complications. There are Very good value.